National Board of Health and Welfare (Sweden)

Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG

Retrieved on: 
Thursday, November 2, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Principal, ASHG, DC, Biomarker, Genotype, CDG, Society, Birth, American Society of Human Genetics, Caregiver, Disease, Annual general meeting, PMM2-CDG, National Board of Health and Welfare (Sweden), Patient, Pharmaceutical industry, Nursing, Glycosylation

Glycomine, Inc. , a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.

Key Points: 
  • Glycomine, Inc. , a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.
  • The findings included genotype characterization, combined with the progression of key biomarkers, over two to four years.
  • The effort has resulted in the largest single dataset in patients with PMM2-CDG from a prospective natural history study to date.
  • PB1696) is “Ongoing Natural History Study in Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG): Clinical and Basic Investigations.”

Cyclarity Therapeutics Announces Clinical Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
MonashHeart, DRS, Intensive care medicine, Biomarker, Monash University, Dean (education), Cardiology, Elias Farkouh, National Board of Health and Welfare (Sweden), Cedars-Sinai Medical Center, Hospital, Coronary care unit, Therapy, VHH, Research, Atherosclerosis, Corporate Affairs, Pharmaceutical industry

Cyclarity Therapeutics, Inc. ( https://cyclaritytx.com ), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

Key Points: 
  • Cyclarity Therapeutics, Inc. ( https://cyclaritytx.com ), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
  • Dr. Michael E. Farkouh, Associate Dean for Research and Clinical Trials and Professor of Cardiology at Cedars-Sinai Hospital.
  • Nicholls, Farkouh and Shah working with us to provide strategic guidance over the preparation and execution of our clinical program,” said Mike Kope, Corporate Affairs CEO of Cyclarity.
  • Cyclarity expects to conduct the UDP-003 Phase 1 trial under the direction of Dr. Nicholls and VHH, and is exploring potential lead site and primary PI roles with Drs.

American Diabetes Association elevates health technology innovation through inaugural event in Silicon Valley

Retrieved on: 
Tuesday, October 3, 2023
Amputation, Kidney failure, Diabetes, Stroke, Ernst & Young, Paratriathlon, Doctor of Philosophy, Royal Bank of Canada, IT Leader Forum, Silicon, BPM, SAN, American Diabetes Association, Showcase, CPA, Association of British HealthTech Industries, Prediabetes, Nerve, ADA, Family, Medtech, National Board of Health and Welfare (Sweden), Disease, Pharmaceutical industry, Video game

The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.

Key Points: 
  • The event begins mid-morning with an Exhibitor Showcase where more than 50 start-ups display their technology or innovation in tabletop presentations.
  • While most of the companies are Silicon Valley/San Francisco Bay Area startups, the event draws applicants from across the country.
  • "The Leaders Forum HealthTech Showcase is what Silicon Valley is about: innovation, technology and progress.
  • "Nearly half of American adults have diabetes or prediabetes, and the impact on the patient, their family, and our society is profoundly underestimated," she continued.

New American Lung Association Research Institute to Accelerate High Impact, Lifesaving Lung Health Science

Retrieved on: 
Tuesday, March 21, 2023
COPD, Tobacco Products Scientific Advisory Committee, Pulmonary Vascular Research Institute, Partnership, Asthma, American Lung Association, COVID-19, Lung cancer, Research, Government, Press release, Canadian Lung Association, Respiratory disease, Research institute, Health, Death, National Board of Health and Welfare (Sweden), Pharmaceutical industry

CHICAGO, March 21, 2023 /PRNewswire/ -- More than 34 million Americans live with lung disease. When combined with lung cancer and respiratory diseases like COVID-19 and influenza, lung disease is a leading cause of death in America. To address urgent and critical lung health challenges in our country, the American Lung Association today announced the launch of the American Lung Association Research Institute.

Key Points: 
  • To address urgent and critical lung health challenges in our country, the American Lung Association today announced the launch of the American Lung Association Research Institute .
  • The American Lung Association Research Institute is our answer to this challenge, and we are committed to investing in research, collaborating with experts and empowering scientists to accelerate discovery and innovation," said Harold Wimmer, President and CEO of the American Lung Association.
  • "The Lung Association has long been the trusted champion of lung health research, and the new Research Institute will take our work to end lung disease to the next level."
  • The new American Lung Association Research Institute will:
    Increase Research Investment through the organization's Awards and Grants program to $25 million per year by 2030.

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

Retrieved on: 
Wednesday, December 7, 2022
Michigan State University, Diversity, Medical degree, Commerce, National Diversity Coalition for Trump, Hematological Cancer Research Investment and Education Act, Laboratory, Health, National Board of Health and Welfare (Sweden), George Washington University, Mount Sinai Medical Center, Biotechnology, Health equity, Cardiology, GeoVax, COVID-19, Vaccine, American Chemistry Council, American Heart Association, Infection, RNA transfection, Inclusion, NIH Director's New Innovator Award, Immunodeficiency, Chemical industry, Abbott Laboratories, Research, Cancer, Morgan, Novartis, Spelman College, Atlanta metropolitan area, Internal medicine, Division, Patient, Toronto Region Board of Trade, AHA, Pharmaceutical industry, Management

ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it has appointed Jayne Morgan, M.D., to its Board of Directors.

Key Points: 
  • Morgan has spearheaded effective outreach initiatives that have greatly influenced and improved public health education and sentiment in target communities, particularly regarding COVID-19,” said David Dodd, Chairman and CEO of GeoVax.
  • Dr. Morgan holds several board positions with the American Heart Association (AHA) including Board Member of its Atlanta Chapter, Board Member of the National Diversity and Inclusion team, National Board Member of the technology team and Regional Board Member of the AHA Health Equity Committee.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases.
  • GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Northwell Holdings and Aegis Ventures Sign Strategic Collaboration Agreement to Launch Upliv, a Comprehensive Digital Health Company for Menopause

Retrieved on: 
Thursday, November 10, 2022
Well, Aegis, Northwell Health, Love, Health, European Menopause and Andropause Society, Hofstra University, Health care, Women's health, Menopause, Intelligence, Holding, Weight gain, Intention, Flash, Total, Neurology, Psychiatry, Fatigue, Practitioner, Brain, NAMS, Patient, Myalgia, Solution, Time, Senior, Nursing, Gaps, Life, Woman, North American Menopause Society, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Cardiology, National Board of Health and Welfare (Sweden), Health insurance, Cryptocurrency, Pharmaceutical industry, Medicine, Management

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Northwell Holdings and Aegis Ventures inked an agreement today for the formation of Upliv, a women's virtual care start-up that aims to raise the bar for clinical menopause support. Upliv will partner with employers to offer virtual telemedicine services and whole-person care to employees experiencing perimenopause and menopause symptoms. Initially, Upliv will offer services to select nurses through a pilot program at Northwell Health, followed by an expected enterprise-wide rollout in the first quarter of 2023.

Key Points: 
  • Upliv is the joint creation of Aegis Ventures and Northwell Holdings, the for-profit investment arm of Northwell Health.
  • In April 2022, Aegis Ventures announced the intention to invest at least $100 million in seed-stage funds towards the development of joint ventures with Northwell Health.
  • Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies.
  • Through strategic partnerships, Holdings leverages the health system's robust enterprise data assets to develop AI-enabled solutions that address healthcare inequities.

Guideway Care Chief Medical Officer Edward E. Partridge, MD Honored at 2022 Beyond Blue Benefit to End Prostate Cancer

Retrieved on: 
Tuesday, September 27, 2022
Oncology, Nursing, Health, Hospitals, Other Health, Managed Care, Health, American Cancer Society, Memory, Prostate, American College, Solution, Organization, Compliance, CMO, Health equity, Patient, Conference USA, Prostate Cancer Foundation of Australia, CEO, Public health, Emeritus, National Board of Health and Welfare (Sweden), Prostate cancer, Board, Research, Conference, Medicine, Commission, SEC, Pleasure, Multimedia, Awareness, Man, Hospital, Pharmaceutical industry, MD, Automated guideway transit, Cancer

A ceremony was hosted by ESPNs Laura Rutledge on Thursday, September 22, 2022, at Protective Life Stadium Club, Birmingham, AL.

Key Points: 
  • A ceremony was hosted by ESPNs Laura Rutledge on Thursday, September 22, 2022, at Protective Life Stadium Club, Birmingham, AL.
  • I am truly blessed and honored to receive this distinctive tribute from an esteemed organization like the Mike Slive Foundation, says Dr. Partridge.
  • Prostate cancer is the most common non-skin cancer affecting one in eight men in their lifetime.
  • For more than 10 years Guideway Care has delivered a proven, scalable technology-enabled Service as a Solution for advancing health equity in Value-Based Care.

BD Names Dr. Joseph M. Smith as Chief Scientific Officer

Retrieved on: 
Monday, November 29, 2021
Patient, CEO, Safety, Disease, Publication, Company, National Board of Medical Examiners, NYSE, Outline of health sciences, BDX, Board of High School and Intermediate Education Uttar Pradesh, Health, Becton, SAB, Johnson & Johnson, Smith, George Washington University School of Engineering and Applied Science, Cardiovascular disease, Solution, Boston Scientific, Internal medicine, Department, Therapy, Conditional sentence, Twitter, Massachusetts Institute of Technology, Organization, American Board of Commissioners for Foreign Missions, Massachusetts, Digital, Efficiency, Biomedical engineering, Science, Medicine, National Board of Health and Welfare (Sweden), LinkedIn, BD, Doctor of Philosophy, Johns Hopkins University, Harvard Medical School, Mike Hopkins (basketball), PDS, Becton, Dickinson and Company headquarters, Management, Pharmaceutical industry

FRANKLIN LAKES, N.J., Nov. 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named senior vice president and chief scientific officer for the company, effective today.

Key Points: 
  • FRANKLIN LAKES, N.J., Nov. 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named senior vice president and chief scientific officer for the company, effective today.
  • Smith will also establish and co-chair the BD Scientific Advisory Board (SAB), which will be comprised of top external medical key opinion leaders, science and technology experts and experienced innovation leaders.
  • Smith reports to Elizabeth McCombs, executive vice president and chief technology officer for BD.
  • During his career, Smith has held medical, scientific and technology leadership positions at multiple organizations including Johnson & Johnson, Boston Scientific and the West Health Institute.